14-day Premium Trial Subscription Sign Up For FreeGet Free

Atara Biotherapeutics Stock Forecast NASDAQ:ATRA

Price Target and Analyst Ratings

Most Recent Rating

JPMorgan Chase & Co. is very positive about ATRA and gave it a "Neutral - Overweight" rating on May 19, 2021. The price target was changed from $23.00 to $29.00.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-05-19 Neutral - Overweight Upgraded by JPMorgan Chase & Co. $14.04 $23.00 → $29.00
2021-05-13 Neutral - Overweight Upgraded by JPMorgan Chase & Co. $14.72 $23.00 → $29.00
2021-05-11 Buy Target Lowered by HC Wainwright $13.91 $32.00 → $31.00
2021-05-05 Buy Target Lowered by HC Wainwright $13.50 $32.00 → $31.00
2021-03-02 Buy Upgraded by Citigroup $16.94 $27.00
2020-12-09 Buy - Neutral Downgraded by Smith Barney Citigroup $23.09 $20.00 → $27.00
2020-12-09 Buy - Neutral Downgraded by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $23.09 $20.00 → $27.00
2020-12-08 Buy Reiterated by HC Wainwright $25.82 $28.00 → $31.00
2020-12-07 Buy Target Raised by Stifel Nicolaus $26.23 $28.00 → $33.00
2020-11-23 Buy Target Raised by Mizuho $23.56 $38.00 → $41.00
2020-11-13 Target Raised by Smith Barney Citigroup $18.05 $14.00 → $20.00
2020-11-13 Target Raised by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $18.05 $14.00 → $20.00
2020-11-10 Buy Target Raised by HC Wainwright $15.58 $26.00 → $28.00
2020-09-24 Buy Reiterated by William Blair $12.55
2020-09-14 Buy Reiterated by Canaccord Genuity $15.03
2020-08-06 Buy Target Lowered by Stifel Nicolaus $12.55 $30.00 → $28.00
2020-08-06 Buy Target Raised by HC Wainwright $12.55 $25.00 → $26.00
2020-07-17 Buy Reiterated by Canaccord Genuity $13.67 $70.00
2020-06-30 Outperform Initiated by Evercore ISI $14.57
2020-06-15 Buy Initiated by HC Wainwright $10.45 $25.00
2020-05-12 Neutral Target Raised by JPMorgan Chase & Co. $10.70 $22.00 → $23.00
2020-04-23 Neutral - Buy Upgraded by Citigroup $8.56 $14.00

ATRA Stock Trend

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $16.06 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -2.39% during the next 3 months and, with a 90% probability hold a price between $11.59 and $15.68 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $11.87 $13.96 $16.06
2021-09-21 $11.86 $13.96 $16.05
2021-09-22 $11.85 $13.95 $16.05
2021-09-23 $11.85 $13.94 $16.04
2021-09-24 $11.84 $13.94 $16.03
2021-09-27 $11.83 $13.93 $16.03
2021-09-28 $11.83 $13.92 $16.02
2021-09-29 $11.82 $13.92 $16.01
2021-09-30 $11.82 $13.91 $16.01
2021-10-01 $11.81 $13.91 $16.00
2021-10-04 $11.80 $13.90 $16.00
2021-10-05 $11.80 $13.89 $15.99
2021-10-06 $11.79 $13.89 $15.98
2021-10-07 $11.78 $13.88 $15.98
2021-10-08 $11.78 $13.87 $15.97
2021-10-11 $11.77 $13.87 $15.96
2021-10-12 $11.77 $13.86 $15.96
2021-10-13 $11.76 $13.86 $15.95
2021-10-14 $11.75 $13.85 $15.95
2021-10-15 $11.75 $13.84 $15.94
2021-10-18 $11.74 $13.84 $15.93
2021-10-19 $11.73 $13.83 $15.93
2021-10-20 $11.73 $13.82 $15.92
2021-10-21 $11.72 $13.82 $15.91
2021-10-22 $11.72 $13.81 $15.91
2021-10-25 $11.71 $13.81 $15.90
2021-10-26 $11.70 $13.80 $15.90
2021-10-27 $11.70 $13.79 $15.89
2021-10-28 $11.69 $13.79 $15.88
2021-10-29 $11.68 $13.78 $15.88

About Atara Biotherapeutics

Atara Biotherapeutics Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases. Its products under development include EBV-CTL, which is Phase II clinical trials for the treatment of malignancies associated with Epstein Barr Virus (EBV), including EBV-associated post-transplant lymphoproliferative disorders; CMV-CTL that is in Phase II clinical trials for the treatme... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT